Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

Table 5

Clinical trials characteristics and results of the association of donepezil plus memantine in moderate-severe AD.

First author and no. in the list of references	Severity	Mean age years	Mean MMSE at baseline	Duration of the study	𝑁	Test
Howard et al. 2012 [29]	MMSE 5–13	77.1±8	9.1±2.6	52 weeks	295	MMSE; BADLS; NPI; PROXY
Doody et al. 2012 [30]	MMSE 0–20	Memantine: 73.6 (8.63); Placebo: 74.0 (8.48)	13.8 (4.63)	24 weeks	1436	MMSE; CIBIC-plus; ACDS-ADL-sev; SIB